Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma

References

• Banchereau J, Palucka K. Immunotherapy: cancer vaccines on the move. Nat Rev Clin Oncol. 2018;15(1):9–10. doi: 10.1038/nrclinonc.2017.149. PMID:28895570.
   PubMed Web of Science ®Google Scholar
• Topalian SL. Targeting immune checkpoints in cancer therapy. JAMA. 2017;318(17):1647–1648. doi: 10.1001/jama.2017.14155. PMID:28885639.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi: 10.1126/science.aaa4967. PMID:25838374.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121–126. doi: 10.1038/nrc.2016.2. PMID:26822578.
   PubMed Web of Science ®Google Scholar
• Kong IC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and Anti-PD-1. Front Immunol. 2014;5:206. doi: 10.3389/fimmu.2014.00206. PMID: 24904570.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–915. PMID: 15340416. doi: 10.1038/nm1100.
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195–1203. PMID:17476349. doi: 10.1172/JCI31205.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48. doi: 10.1016/j.immuni.2013.07.004. PMID:23890062.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, Van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–67. doi: 10.1016/S1470-2045(13)70585-0. PMID:24872109.
   PubMed Web of Science ®Google Scholar
• Bol KF, Schreibelt G, Gerritsen WR, De Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22(8):1897–1906. doi: 10.1158/1078-0432.CCR-15-1399. PMID:27084743.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95. doi: 10.1038/cr.2016.157. PMID:28025976.
   PubMed Web of Science ®Google Scholar
• Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2017;6(7):e1328341. doi: 10.1080/2162402X.2017.1328341. PMID:28811970.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, De Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7(10):790–802. PMID:17853902. doi: 10.1038/nri2173.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Andre F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Invest. 2016;126(4):1224–1232. doi: 10.1172/JCI81137. PMID:27035813.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014; 6(232):232ra51. doi: 10.1126/scitranslmed.3008068. PMID:24739759.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411–422. doi: 10.1056/NEJMoa1001294. PMID:20818862.
   PubMed Web of Science ®Google Scholar
• Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, et al. CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncoimmunology. 2016; 5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. PMID:27471645.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf IG. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol. 2006;18(8):1279–1283. PMID:16772371. doi: 10.1093/intimm/dxl059.
   PubMed Web of Science ®Google Scholar
• Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? Oncologist. 2012;17(10):1256–1270. doi: 10.1634/theoncologist.2011-0122. PMID:22907975.
   PubMed Web of Science ®Google Scholar
• Yan L, Wu M, Ba N, Wang LJ, Zhang HQ, Shi GY, Zhang ZS, Wang XJ. Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma. Genet Mol Res. 2015;14(1):898–905. doi: 10.4238/2015. PMID:25730028.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, et al. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004;172(8):4762–4769. PMID:15067052.
   PubMed Web of Science ®Google Scholar
• Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, Kriegeskorte A, Busch DH, Röcken M, Mocikat R. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005;106(1):338–344. PMID: 15769894. doi: 10.1182/blood-2004-09-3775.
   PubMed Web of Science ®Google Scholar
• Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, et al. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006; 55(6):663–671. PMID: 16133107. doi: 10.1007/s00262-005-0065-y.
   PubMed Web of Science ®Google Scholar
• Karimi K, Boudreau JE, Fraser K, Liu H, Delanghe J, Gauldie J, Xing Z, Bramson JL, Wan Y. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther. 2008;16(2):411–418. PMID:18059374. doi: 10.1038/sj.mt.6300347.
   Web of Science ®Google Scholar
• Collignon A, Perles-Barbacaru AT, Robert S, Silvy F, Martinez E, Crenon I, Germain S, Garcia S, Viola A, Lombardo D, et al. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget. 2015; 6(27):23462–23479. PMID:26405163. doi: 10.18632/oncotarget.4359.
   PubMedGoogle Scholar
• Simon T, Fonteneau JF, Gregoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy. 2009;1(2):289–302. doi: 10.2217/1750743X.1.2.289. PMID:20635946.
   PubMed Web of Science ®Google Scholar
• Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, Von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One. 2011;6(4):e18801. doi: 10.1371/journal.pone.0018801. PMID:21533099.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood. 2015; 125(1):82–89. doi: 10.1182/blood-2014-07-592162. PMID:25293773.
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5(4):405–411. PMID:10202929. doi: 10.1038/7403.
   PubMed Web of Science ®Google Scholar
• Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006;177(12):8448–8455. PMID:17142742.
   PubMed Web of Science ®Google Scholar
• Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, Thomas EK, Nickoloff BJ, Mulé JJ. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 2001;61(1):228–236. PMID:11196166.
   PubMed Web of Science ®Google Scholar
• Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009;4(3):e4942. PMID:19319200. doi: 10.1371/journal.pone.0004942.
   PubMed Web of Science ®Google Scholar
• Hanke N, Alizadeh D, Katsanis E, Larmonier N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol. 2013;33(1):1–21. PMID:23510023.
   PubMed Web of Science ®Google Scholar
• Chiaravalli M, Reni M, O’Reilly EM. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies. Cancer Treat Rev. 2017;60:32–43. doi: 10.1016/j.ctrv.2017.08.007. PMID:28869888.
   PubMed Web of Science ®Google Scholar
• Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476–1481. doi: 10.1136/gutjnl-2015-309304. PMID:25994217.
   PubMed Web of Science ®Google Scholar
• Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Advances in inducing adaptive immunity using cell-based cancer vaccines: clinical applications in pancreatic cancer. World J Gastroenterol. 2016;22(18):4446–4458. doi: 10.3748/wjg.v22.i18.4446. PMID:27182156.
   PubMed Web of Science ®Google Scholar
• Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett. 2006;103(2):142–148. PMID:16313973. doi: 10.1016/j.imlet.2005.10.021.
   PubMed Web of Science ®Google Scholar
• Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A, Dauer M. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut. 2007;56(9):1275–1282. PMID:17395611. doi: 10.1136/gut.2006.108621.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003;63(24):8962–8967. PMID:14695214.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Collignon A, Isnardon D, Benkoel L, Verine A, Silvy F, Bernard JP, Lombardo D, Beraud E, Olive D. A novel tumor-associated pancreatic glycoprotein is internalized by human dendritic cells and induces their maturation. J Immunol. 2011;186(7):4067–4077. doi: 10.4049/jimmunol.1000408. PMID:21346236.
   PubMed Web of Science ®Google Scholar
• Beraud E, Collignon A, Franceschi C, Olive D, Lombardo D, Mas E. Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer. Oncoimmunology. 2012;1(1):56–61. PMID:22720212. doi: 10.4161/onci.1.1.18459.
   PubMed Web of Science ®Google Scholar
• Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol. 2017;10(8):631–645. doi: 10.1177/1756283X17713879. PMID:28835777.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17(6):801–810. doi: 10.1016/S1470-2045(16)00172-8. PMID:27160474.
   PubMed Web of Science ®Google Scholar
• Hessmann E, Johnsen SA, Siveke JT, Ellenrieder V. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2017;66(1):168–179. doi: 10.1136/gutjnl-2016-312539. PMID:27811314.
   PubMed Web of Science ®Google Scholar
• Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162(1):168–175. PMID:9886383.
   PubMed Web of Science ®Google Scholar
• Hochrein H, O’Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, Shortman K. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med. 2000;192(6):823–833. PMID:10993913.
   PubMed Web of Science ®Google Scholar
• Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693–1702. PMID:1460426.
   PubMed Web of Science ®Google Scholar
• Lutz MB. IL-3 in dendritic cell development and function: a comparison with GM-CSF and IL-4. Immunobiology. 2004;209(1–2):79–87. PMID:15481143. doi: 10.1016/j.imbio.2004.03.001.
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701–738. PMID:10358772. doi: 10.1146/annurev.immunol.17.1.701.
   PubMed Web of Science ®Google Scholar
• Yin SY, Wang CY, Yang NS. Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage. Exp Cell Res. 2011;317(15):2210–2221. doi: 10.1016/j.yexcr.2011.06.013. PMID:21741972.
   PubMed Web of Science ®Google Scholar
• Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005;106(2):609–616. PMID:15802534. doi: 10.1182/blood-2004-10-3906.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–146. PMID:12563297. doi: 10.1038/nri1001.
   PubMed Web of Science ®Google Scholar
• Dubois SP, Waldmann TA, Muller JR. Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci U S A. 2005;102(24):8662–8667. PMID:15932944. doi: 10.1073/pnas.0503360102.
   PubMed Web of Science ®Google Scholar
• Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med. 2004;200(7):825–834. PMID:15452177. doi: 10.1084/jem.20041389.
   PubMed Web of Science ®Google Scholar
• Van Acker HH, Anguille S, Willemen Y, Van Den Bergh JM, Berneman ZN, Lion E, Smits EL, Van Tendeloo VF. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol. 2016;9(1):101. PMID:27686372. doi: 10.1186/s13045-016-0329-3.
   PubMedGoogle Scholar
• Srivastava S, Salim N, Robertson MJ. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem. 2010;17(29):3353–3357. PMID:20712569.
   PubMed Web of Science ®Google Scholar
• Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J Immunol. 2010;184(4):1876–1884. doi: 10.4049/jimmunol.0900831. PMID:20089706.
   PubMed Web of Science ®Google Scholar
• Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT, Baar J. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J Immunother. 2002;25(3):226–234. PMID:12000864.
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006; 12(2):214–219. PMID:16444265. doi: 10.1038/nm1356.
   PubMed Web of Science ®Google Scholar
• Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D, Thiesen HJ, Löhr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas. 2001;23(1):72–79. PMID:11451151.
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009; 119(5):1251–1263. doi: 10.1172/JCI36022. PMID:19349689.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Borst J. The opposing roles of CD4+ T cells in anti-tumour immunity. Immunology. 2018; doi: 10.1111/imm.12941. PMID: 29700809.
   Web of Science ®Google Scholar
• Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112–3126. PMID:14681207. doi: 10.1101/gad.1158703.
   PubMed Web of Science ®Google Scholar
• Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol. 2002;168(4):1831–1839. PMID:11823516.
   PubMed Web of Science ®Google Scholar
• Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204(6):1441–1451. PMID:17535975. doi: 10.1084/jem.20070021.
   PubMed Web of Science ®Google Scholar
• Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, Lauvau G, Zitvogel L, Martin F, Chauffert B, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest. 2008; 118(11):3751–3761. doi: 10.1172/JCI35890. PMID:18830416.
   PubMed Web of Science ®Google Scholar
• Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012;1(7):1074–1083. PMID:23170255. doi: 10.4161/onci.20897.
   PubMed Web of Science ®Google Scholar
• Anguille S, Lion E, Tel J, De Vries IJ, Coudere K, Fromm PD, Van Tendeloo VF, Smits EL, Berneman ZN. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One. 2012;7(12):e51851. doi: 10.1371/journal.pone.0051851. PMID:23284789.
   PubMed Web of Science ®Google Scholar
• Hill KS, Errington F, Steele LP, Merrick A, Morgan R, Selby PJ, Georgopoulos NT, O’Donnell DM, Melcher AA. OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol. 2008;181(5):3108–3115. PMID:18713981.
   PubMed Web of Science ®Google Scholar
• Larmonier N, Bonnotte B, Katsanis E. Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. Oncoimmunology. 2012;1(4):566–568. PMID:22754789.
   PubMed Web of Science ®Google Scholar
• Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology. 2018;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. PMID: 29399398.
   PubMed Web of Science ®Google Scholar
• Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657–679. PMID:16551262. doi: 10.1146/annurev.immunol.24.021605.090727.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA. Harnessing NK cell memory for cancer immunotherapy. Trends Immunol. 2016;37(12):877–888. doi: 10.1016/j.it.2016.09.005. PMID: 27773685.
   PubMed Web of Science ®Google Scholar
• Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000;60(8):2209–2217. PMID:10786686.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Fu Z, Yin H. A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs. J Biotechnol. 2013;166(4):166–173. doi: 10.1016/j.jbiotec.2013.05.008. PMID:23747489.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2016;113(8):2200–2205. doi: 10.1073/pnas.1600421113. PMID:26858448.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 2011; 60(3):341–349. doi: 10.1136/gut.2010.211722. PMID:20855451.
   PubMed Web of Science ®Google Scholar
• Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut. 2008; 57(10):1420–1430. doi: 10.1136/gut.2007.148189. PMID:18515410.
   PubMed Web of Science ®Google Scholar
• Bonnotte B, Larmonier N, Favre N, Fromentin A, Moutet M, Martin M, Gurbuxani S, Solary E, Chauffert B, Martin F. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol. 2001;167(9):5077–5083. PMID: 11673517.
   PubMed Web of Science ®Google Scholar